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Abstract:  To elucidate the effect of a large dose of di (2-ethylhexyl) phthalate (DEHP), a plasticizer and peroxisome
proliferator-activated receptor-α (PPARα) agonist, on hepatic peroxisomes, we orally administered 1,000 mg/kg/day,
once daily, to 3 male and 4 female cynomolgus monkeys for 28 days consecutively.  Light-microscopic and electron
microscopic examinations of the liver were carried out in conjunction with measurement of the hepatic fatty acid β-
oxidation system (FAOS), carnitine acetyltransferase (CAT) and carnitine palmitoyltransferase (CPT) activities, which
are peroxisomal and/or mitochondrial enzyme activities.  Electron microscopically, enlargement of the mitochondria was
observed with lamellar orientation of the cristae along the major axis.  Although the number of peroxisomes showed a
tendency to increase when compared with those in a biopsied specimen before treatment, no abnormality in morphology
was observed.  A slight increase in CPT activity was noted at termination.  No changes were noted in hepatic FAOS or
CAT activity.  In conclusion, although repeated oral treatment of cynomolgus monkeys with a large dose of DEHP
induced a subtle increase in the numbers of peroxisomes with slight enlargements of the mitochondria, this low-
sensitivity response to peroxisome proliferators in cynomolgus monkeys was considered to be closer to the response in
humans than that in rodents. (J Toxicol Pathol 2010; 23: 75–83)
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Introduction
Species differences in response to peroxisome
proliferators including fibrates as hypolipidemic agents are
well-known1–4.  Generally, rodents such as mice and rats
exhibit a high susceptibility to these peroxisome
proliferators with consequent hepatomegaly and
hepatocarcinogenesis1–4.  However, nonhuman primates
showed no such sensitivity5, 6 according to the report of
Reddy et al.7; on the other hand, the fibrate derivative
ciprofibrate evoked hepatic peroxisome proliferation in
cynomolgus and rhesus monkeys, pigs, cats and chickens.
Similarly, Hoivik et al.8 confirmed that treatment of
cynomolgus monkeys with high doses of fenofibrate or
ciprofibrate caused hepatic peroxisome proliferation in a
dose-dependent manner.  Therefore, it was considered that
nonhuman primates would be likely to possess a
proliferative reaction, although it would be a minor response.
Di (2-ethylhexyl) phthalate (DEHP), a plasticizer and
its metabolites are peroxisome proliferator-activated
receptor-α (PPARα) agonist, has previously been shown to
induce peroxisomal proliferation in the livers of rats when
administered at 100 mg/kg/day for 14 and 21 days9,10.  In
contrast, it has been reported that DEHP did not provoke
such alterations in the livers of marmosets and cynomolgus
monkeys when administered at 2,500 mg/kg/day for 13
weeks11 and at 500 mg/kg/day for 14 or 21 days9,12,
respectively.  Accordingly, cynomolgus monkeys were not
treated with a higher dose of DEHP in these studies.  In our
previous study13, repeated oral treatment of cynomolgus
monkeys with a large dose (1,000 or 2,500 mg/kg/day) of
DEHP showed a tendency to increase peroxisome
proliferation in hepatocytes; however, a small number of
animals was used without any corresponding control.
Additionally, at 1,000 mg/kg/day of DEHP, body weight
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deceased by around 10%, and enlargement of the
mitochondria with lamellar orientation of the cristae along
the major axis was observed in two females.  A dosage level
of 2,500 mg/kg/day was not considered to be feasible
because the body weight decreased by approximately 40%
and hepatic atrophy was observed in one female.  These
findings implied that an appropriate evaluation could not be
carried out, and 1,000 mg/kg/day was thought to be the
upper limit in cynomolgus monkeys.  In the present
investigation, therefore, to elucidate whether a high dose of
DEHP evokes peroxisomal proliferation with mitochondrial
alterations in cynomolgus monkeys, we orally administered
a high dose (1,000 mg/kg/day) of DEHP to both sexes for 28
days consecutively.
Materials and Methods
The present study was approved by the Institutional
Animal Care and Use Committee and was conducted in
accordance with the bylaws of the committee.
Chemicals
Di (2-ethylhexyl) phthalate (DEHP, Lot No. 4YNPE)
was purchased from Tokyo Chemical Industry Co., Ltd.
(Tokyo, Japan).  All other chemicals and reagents were of
the highest grade available from commercial sources, unless
otherwise stated. 
Animals and housing conditions
Six male and seven female cynomolgus monkeys
(Macaca fascicularis) that were 3- to 5-year-olds, purpose-
bred and from China were used.  They were housed
individually in stainless steel cages (680 mm D × 620 mm W
× 770 mm H) with an artificial lighting cycle of 12 hr (06:00
to 18:00), a temperature range of 23 to 29°C, a humidity
range of 35 to 75% and 15 ventilation cycles/hour.
Approximately 108 g (12 g × 9 pieces) of pellet food (Teklad
Global Certified 25% Protein Primate Diet, Harlan Sprague
Dawley Inc., Indianapolis, IN, USA) was provided to each
animal once daily.  The remaining food was removed before
dosing on the following day.  Drinking water was available
ad libitum from an automatic supply system.
During a 4-week-acclimation period, drinking water (15
mL/kg) was administered by gavage to each animal daily
from 3 days before the initiation of dosing in the same manner
as test article administration to acclimate the animal to the
dosing procedure.  The day before the initiation of dosing was
designated as day minus 1 (day –1), the week before the
initiation of dosing was designated as week minus 1 (week –
1) and the first day of dosing was designated as day 1.
Liver biopsy
Liver biopsy for electron microscopy was conducted for
all animals in the first week of the acclimation period (day –
29, –26 or –25).  A portion of liver tissue (approximately 0.5
g) was removed with an electric knife (MESU-150, Mizuho
Ikakogyo Co. Ltd., Tokyo, Japan) under ketamine
hydrochloride anesthesia (50 mg/mL, 0.2 mL/kg, Kamud
Drugs Pvt. Ltd., Navi Mumbai, India).
Experimental design
DEHP was administered orally once daily to three
males and four females for 28 days consecutively at a dose
level of 1,000 mg/kg/day by a nasogastric catheter (Size:
10Fr, Nipro Corporation, Osaka, Japan).  DEHP was
dissolved in corn oil at concentrations of 200 mg/mL.  Three
males and three females receiving corn oil (5 mL/kg/day) in
the same manner as the DEHP group served as the vehicle
control (Table 1).
During the dosing period, clinical signs were observed
three times daily.  Body weight was measured twice a week.
Food consumption was measured daily.  For food
consumption, weekly mean values were calculated as g/
animal/day.
Clinical pathology
Hematology and blood chemistry were conducted twice
during the acclimation period and once on day 26 of dosing.
In blood, the erythrocyte count, leukocyte count, hematocrit
value, hemoglobin concentration, reticulocyte ratio and
differential leukocyte count were determined using a
hematology system (ADVIA120: Siemens Healthcare
Diagnostics, Tarrytown, NY, USA).  In serum, aspartate
aminotransferase, alanine aminotransferase, alkaline
phosphatase, lactate dehydrogenase, creatine
phosphokinase, total bilirubin, total protein, albumin,
globulin, albumin/globulin ratio, total cholesterol,
triglycerides, glucose, blood urea nitrogen, creatinine,
inorganic phosphorus, calcium, sodium, potassium and
chloride were quantified using an automatic analyzer (JCA-
BM8: JEOL Ltd., Tokyo, Japan).
Toxicokinetics
Approximately 0.5 mL of blood was collected from the
Table 1. Experimental Design
Test articles Dose level Volume Concentration Number of animals (Animal No.)
(mg/kg/day) (mL/kg/day) (mg/mL) Males Females
Corn oil* – 5 – 3 (1 to 3) 3 (4 to 6)
DEHP* 1000 5 200 3 (7 to 9) 4 (10 to13)
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femoral vein of each animal including those in the vehicle
control group using a syringe containing sodium heparin
prior to dosing and 1, 2, 4, 6 and 24 hr after dosing on day 26.
The blood samples were immediately cooled on ice and
centrifuged at 4°C at 1,710 × g for 15 min to obtain plasma.
The plasma was stored frozen at –10°C or below until it was
analyzed.
Concentrations of DEHP and its first metabolite, mono
(2-ethylhexyl) phthalate (MEHP), in plasma were
determined by a high-performance liquid chromatography
(HPLC) system with a UV detector (Alliance#2795, Waters
Corporation, Milford, MA, USA).  The area under the
plasma concentration-time curve until 24 hr after the 26th
dosing (AUC0-24h) for MEHP was calculated by the linear
trapezoidal rule.
Necropsy
All animals were euthanized by exsanguination under
sodium pentobarbital anesthesia (64.8 mg/mL, 0.4 mL/kg,
Tokyo Chemical Industry Co., Ltd., Tokyo, Japan) 24 hr
following the final dosing.  At necropsy, external
appearance, internal organs and tissues were examined
macroscopically.  The livers were removed and weighed
using an electronic balance (HF-3000, A & D Co., Ltd., San
Jose, CA, USA).  The relative liver weight was calculated
from the body weight on the day of necropsy.  Liver tissue
was collected for measurement of the below-stated
peroxisomal enzyme activities and light and electron
microscopy.
Measurement of hepatic peroxisomal and 
mitochondrial enzyme activities
The right lobe of the liver was perfused with ice-cold
physiological saline, frozen immediately with liquid
nitrogen and stored in a freezer at –70°C or below before
being assayed.
All procedures described below were conducted under
ice-cold conditions.  After the collected liver tissue was cut
into small portions with scissors, an amount of Tris buffer
containing 1 mmol/L EDTA (pH 7.4) equal to nine times the
liver tissue weight was added.  The tissue was homogenized
to prepare a 10% hepatic homogenate.
The activities of fatty acid β-oxidation system (FAOS),
carnitine acetyltransferase (CAT) and carnitine
palmitoyltransferase (CPT) in the 10% hepatic homogenates
were measured by a spectrophotometer (U-3010, Hitachi,
Ltd., Tokyo, Japan) using a previously reported method14.
Each activity is reported as μmol/min/g liver.
Light microscopy
After excision at necropsy, the liver was fixed in 10%
neutral buffered formalin and embedded in paraffin wax.
Approximately 4-μm paraffin sections were stained with
hematoxylin and eosin (HE) and examined microscopically.
Electron microscopy
The portions of liver tissue obtained by biopsy before
treatment and after exsanguination at necropsy were fixed in
2.5% glutaraldehyde and 1% osmium tetroxide and
embedded in epoxy resin (Quetol 812).  Ultra-thin
specimens (0.05 to 0.1 μm) were stained with uranyl acetate
and lead citrate and examined by transmission electron
microscopy (JEM-1200EX, JEOL, Ltd., Tokyo, Japan).
The numbers of peroxisomes and mitochondria in the
hepatocytes in the centrilobular or periportal area in 40
images of liver tissue were counted at 6,500 × magnification
for each animal.  The total area of the 40 images was
approximately 3,300 μm2.
Statistical analysis
Quantitative data were analyzed statistically to compare
the vehicle control and DEHP groups.  Additionally, the data
from electron microscopy were analyzed to compare the
values from before and after repeated treatment.  They were
first analyzed for homogeneity of variance by Bartlett’s test.
When the variance was homogeneous, a one-way analysis of
variance was applied.  When the result was significant,
Dunnett’s test was applied.  When the variance was
heterogeneous by Bartlett’s test, the data were analyzed by
the Kruskal-Wallis test.  When the result was significant, a
Dunnett-type test was applied.  The MUSCOT statistical
analysis software (Yukms Co., Ltd., Tokyo, Japan) was used
for these statistical analyses at a significance level of 5%.
Results
Pathological findings in the liver
In macroscopic and light microscopic examinations, no
abnormality related to DEHP treatment was observed.
In regard to organ weights, no statistically significant
differences were noted the liver; however, slight increases
both in absolute and relative weights were noted in two
females (Animal Nos. 10 and 13) that showed no body
weight loss in the DEHP group (Table 2).  The increase
ratios were 22 or 24% for the relative weight when compared
with the mean values in the corn oil group.  The relative
weight of 1 other female (Animal No. 11) in the DEHP
group increased; however, the absolute weight did not
increase, and body weight loss was observed in this animal.
Electron-microscopically, enlargement of the
mitochondria with lamellar orientation of the cristae along
the major axis was observed in one female (Animal No. 13)
in the DEHP group (Fig. 1).  Some mitochondria showed
elongated enlargement.
In the DEHP-treated females, the numbers of
peroxisomes in both centrilobular and periportal areas
increased significantly (**p<0.01) at the end of the dosing
period compared with those before treatment (Fig. 2).  The
individual increase ratios were 33.3% to 111.4% and 38.5%
to 81.3% in the centrilobular and periportal areas,
respectively; however, no significant changes were noted in
mitochondria (Fig. 3).  In the DEHP-treated males, no
statistically significant differences in the numbers of
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numbers of peroxisomes in the periportal area showed a
tendency to increase; i.e., the mean value was higher than
those before treatment or in the corn oil group (Fig. 2, 3).
Hepatic peroxisomal and mitochondrial enzymes
The activity of the mitochondrial enzyme CPT
increased significantly in the males treated with DEHP, at
1.6 fold higher (2.043 units for corn oil versus 3.313 units for
DEHP).  No statistically significant differences were
observed in the FAOS or CAT activities (Fig. 4).
Toxicokinetics
Extremely low concentrations (2.0–9.0 μg/mL) of the
parent compound DEHP in plasma were detected
sporadically at 1 to 6 hr after dosing in two males and two
females in the DEHP group.  Meanwhile, its first metabolite,
MEHP, increased with time after dosing in all animals in the
DEHP group.  The plasma MEHP concentration reached a
maximum at 4 to 6 hr after dosing.  The individual Cmax
values ranged from 39.2 to 70.5 μg/mL, and the mean Cmax
value in the DEHP group was 51.3 ± 10.8 μg/mL.  The
individual AUC0-24h values ranged from 517.6 to 1374.2
μg·hr/mL, and the mean AUC0–24h in the DEHP group was
826.6 ± 271.2 μg·hr/mL.
Clinical observations and laboratory tests
In regard to clinical signs, as abnormalities related to
DEHP treatment, soft stool and/or diarrhea were observed in
all males and females almost every day.  Vomiting was
observed in one male and one female on day 3 or 26.
In regard to body weight, a decrease was observed in
two males and one female (Animal Nos. 8, 9 and 11) in the
DEHP group at the end of the dosing period when compared
with the first day of dosing (Fig. 5).  The decrease ratios in
these animals were 10.0%, 15.5% and 24.2%.  No
abnormalities were observed in any other animal.
In regard to food consumption, the mean values of food
consumption throughout the dosing period were decreased in
one male and one female (Animal Nos. 9 and 11) in the
DEHP group.  The decrease ratios of the mean values in
these animals were 43% and 44%, respectively, when
compared with the mean values in weeks –2 to –1.  No
abnormalities were observed in any other animal.
In regard to blood chemistry, serum lipids (total
cholesterol or triglyceride) did not decrease in the DEHP
group (Table 3).  An increase in triglycerides was noted in 1
Table 2. Organ Weights of the Livers of Cynomolgus Monkeys Orally Administrated Corn Oil or DEHP at 1,000 mg/kg/
day for 28 Consecutive Days
Absolute Weight
Male Female
Group Animal No. (g) Animal No. (g)
Corn oil 1 70.6 4 59.4
2 70.4 5 44.7
3 79.4 6 61.5
Mean ± SD 73.47 ± 5.14 Mean ± SD 55.20 ± 9.15
DEHP 7 81.1 10 66.2
8 65.3 11 57.2
9 68.0 12 48.9
– – 13 71.9 
Mean ± SD 71.47 ± 8.45 Mean ± SD 61.05 ± 10.11
Not significantly different from the corn oil group.
Relative Weight per Body Weight
Male Female
Group Animal No. (g/kg) Animal No. (g/kg)
Corn oil 1 16.2 4 22.0
2 17.8 5 19.0
3 20.7 6 18.9
Mean ± SD 18.23 ± 2.30 Mean ± SD 19.98 ± 1.75
DEHP 7 19.7 10 24.4
8 20.2 11 25.8
9 21.1 12 20.0
– – 13 24.7
Mean ± SD 20.34 ± 0.71 Mean ± SD 23.74 ± 2.53
Not significantly different from the corn oil group.
↓
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female (Animal No. 11) in the DEHP group.  In regard to
hematology, no abnormality related to DEHP treatment was
observed.
Discussion
Statistically significantly increased numbers of
peroxisomes in the centrilobular and periportal areas were
observed in the DEHP-treated females compared with before
treatment.  In the DEHP-treated males, no statistically
significant differences were noted; however, the numbers of
peroxisomes in the periportal area were higher than those
before treatment or in the corn oil group.  These results
suggested that a large dose of DEHP induced an increase in
the numbers of peroxisomes.  On the other hand, no
significant differences were observed when compared with
the corn oil group in the numbers of peroxisomes in the
males or females.  No differences were observed in the
peroxisomal enzyme activities in liver homogenates between
the DEHP and corn oil groups.  These results suggested that
the peroxisome proliferation was subtle.  In our previous
study13, we could not reach a conclusion as to whether or not
DEHP induced peroxisome proliferation.  We added the
Fig. 2. Number of hepatic peroxisomes in cynomolgus monkeys
orally administrated DEHP at 1,000 mg/kg/day for 28
consecutive days.  Monkeys given corn oil in the same
manner served as the vehicle control.  Columns and vertical
bars show the mean values and SD of 3–7 animals,
respectively.  ** P<0.01: significantly different from the
values at pretreatment.
Fig. 1. Electron microphotographs of periportal hepatocytes in a
female cynomolgus monkey orally administrated DEHP at
1,000 mg/kg/day for 28 consecutive days.  (A) Before
treatment: No abnormal changes were observed.  (B) Same
animal after treatment: Peroxisomes increased in the
hepatocyte.  Lamellar orientation of cristae along the major
axis was observed in the enlarged mitochondria (arrows).
(C) Same animal after treatment: The mitochondria showed
elongated enlargement.  Lamellar orientation of cristae along
the major axis was observed in the enlarged mitochondria
(arrows).  P: Peroxisome.80 Peroxisome Proliferation in the Liver Induced by DEHP
biopsy before treatment and a vehicle control and increased
the number of animals in the present study.  As a
consequence, we were able to conclude that DEHP induced
a subtle change in hepatic peroxisome proliferation in the
cynomolgus monkeys.
In our previous study13, morphological changes of
mitochondria, such as enlargement and lamellar orientation
of the cristae along the major axis, were observed in 2 female
cynomolgus monkeys whose body weights decreased at
ratios of 10.7% or 11.7% at 1,000 mg/kg/day of DEHP, and
the possibility that malnutrition could have caused the
mitochondrial changes was suggested.  In the present study,
mitochondrial abnormalities were observed in one female;
however, body weight loss was not noted in this animal.
Mitochondrial changes caused by peroxisome proliferators
have previously been reported as follows: DEHP induced
increases in both the size and number of mitochondria in
hepatocytes in rats15,16, and other PPARα agonists
(ciprofibrate and fenofibrate) induced an increase in number
Fig. 4. Fatty acid β-oxidation system (FAOS), carnitine
acetyltransferase (CAT) and carnitine palmitoyltransferase
(CPT) activities in the liver homogenates of cynomolgus
monkeys orally administrated DEHP at 1,000 mg/kg/day for
28 consecutive days.  Monkeys given corn oil in the same
manner served as the vehicle control.  Columns and vertical
bars show the mean values and SD of 3 or 4 animals,
respectively.  * P<0.05: significantly different from the corn
oil group.
Fig. 3. Number of hepatic mitochondria in cynomolgus monkeys
orally administrated DEHP at 1,000 mg/kg/day for 28
consecutive days.  Monkeys given corn oil in the same
manner served as the vehicle control.  Columns and vertical
bars show the mean values and SD of 3–7 animals,
respectively.
Fig. 5. Body weights of cynomolgus monkeys orally administrated
DEHP at 1,000 mg/kg/day for 28 consecutive days.Satake, Nakamura, Minamide et al. 81
and elongation of mitochondria in hepatocytes in
cynomolgus monkeys8.  Additionally, peroxisome and
mitochondria are closely associated with each other in
PPARα agonist-related metabolism.  Consequently, there is
a high possibility that the mitochondrial changes observed in
the present study were caused by effects of DEHP on the
hepatocytes.  The toxicological significance and mechanism
of the mitochondrial changes were unclear in the present
study, and other approaches from the standpoint of
molecular biology would seem to be required.
CPT is widely known to be a fatty acid oxidation rate-
limiting enzyme in the mitochondria.  Hepatic CPT activity
increased in males treated with DEHP but not in females,
and morphological changes of the mitochondria were
observed only in females.  Thus, the relation between the
morphological changes of the mitochondria and increased
activity of CPT was unclear.  It has been reported that
PPARα agonists such as fibrates increase hepatic CPT,
FAOS and CAT activities two- to five-fold or more and
decrease serum lipids in rats17.  In the present study, CPT
activity increased 1.6-fold in the males; however, serum
lipids did not decrease.  An increase in triglycerides was
noted in 1 female in the DEHP group; however, this was
considered to be related innutrition because decreases in
food consumption and body weight were noted in this
animal.
In the present study and our previous study13,
peroxisomal proliferation and mitochondrial changes were
clearer in females than in males.  The changes in both the
females and males were slight.  Consequently, the differences
between females and males were slight; however, there seem
to be sex-related differences in the response to peroxisome
proliferators in cynomolgus monkeys.  Sex differences in
response to peroxisome proliferators such as crofibrate have
been reported in rats18, 19.  Male rats are more sensitive than
females, and it has been suggested that this is due to the
influence of testosterone18.  The result in the present study
differed from the previously reported results in rats.  It is
possible that factors other than testosterone had an influence
in the cynomolgus monkeys, but this was uncertain.
A number of experiments have suggested that there are
species differences in the expression of PPARα and
response to PPARα agonists (including differences in
receptor activation, peroxisome proliferation and induction
of target genes), which are higher in rodents than in other
species20–26.  Additionally, there is a wide range of receptor
Table 3. Serum Lipids in Cynomolgus Monkeys Orally Administrated Corn Oil or DEHP at 1,000 mg/kg/day for 28 Consecutive Days
Total cholesterol Triglyceride
(mg/dL) (mg/dL)
Group Animal No./Day Day –5* Day 26* Day –5* Day 26*
Control (Male)
Corn oil 1 122 111 59 33
27 6 7 9 3 5 3 9
3 137 137 48 40
Mean 111.7 109.0 47.3 37.3
SD 31.8 29.1 12.0 3.8
DEHP (Male)
1,000 mg/kg/day 7 93 84 26 22
89 2 9 3 4 3 3 7
9 74 103 14 34
Mean 86.3 93.3 27.7 31.0
SD 10.7 9.5 14.6 7.9
Control (Female)
Corn oil 4 153 157 34 18
5 129 117 44 49
6 126 126 29 49
Mean 136.0 133.3 35.7 38.7
SD 14.8 21.0 7.6 17.9
DEHP (Female)
1,000 mg/kg/day 10 156 136 33 35
11 175 195 52 285
12 136 123 27 41
13 139 137 24 25
Mean 151.5 147.8 34.0 96.5
SD 18.0 32.1 12.6 125.8
Not significantly different from the corn oil group.
*: The day before initiation of dosing was designated as day –1, and the first day of dosing was designated as day 1.
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affinities for different PPARα ligands26.  The lower
reactivity of cynomolgus monkeys to DEHP may be
explained by these differences.
MEHP is the first metabolite of DEHP and is a PPARα
agonist.  The first stage in metabolism of DEHP is hydrolysis
to MEHP and 2-ethylhexanol.  Hydrolysis to MEHP rapidly
takes place in the intestine, and further hydrolysis takes place
after absorption27,28.  Additionally, hydrolysis to MEHP by
plasma lipase takes place in blood samples29.  The DEHP
and MEHP concentrations in plasma might not have shown
pharmacokinetically true values because there is a
possibility that hydrolysis to MEHP took place during the
procedure for obtaining plasma and/or its preservation.
However, the increased plasma MEHP level revealed
sufficient intestinal absorption of DEHP in the present study.
In the present study, we concluded that DEHP induced
hepatic peroxisome proliferation in cynomolgus monkeys;
however, the degree of increase was very low, hepatomegaly
or hepatic proliferation was not observed and the exposure
level was extremely high (1,000 mg/kg/day).  In contrast,
peroxisome proliferation was observed from 100 mg/kg/day
in rats9,10.  At the same time, our results reconfirmed that
cynomolgus monkeys are sensitive to peroxisome
proliferators.  Reddy et al.7 and Hoivik et al.8 reported that
treatment with high doses of fenofibrate or ciprofibrate
caused hepatic peroxisome proliferation in cynomolgus
monkeys.  In humans, previous investigations have reported
that human hepatocytes are insensitive to peroxisome
proliferators30,31.  On the other hand, Ganning et al.32,33
reported that liver biopsies taken from dialysis patients
showed hepatic peroxisome proliferation and concluded that
this was caused by phthalate esters having migrated from
tubes or bags that were made of polyvinyl chloride plastics.
In their reports, although quantitative data for the
peroxisome count was not reported, peroxisome
proliferation in humans was considered to be subtle based on
electron micrographs32,33.  We can assume that hepatic
peroxisome proliferation in human resulting from DEHP is
subtle, just as in the case of cynomolgus monkeys.  There
have been no reports showing that peroxisome proliferators
induce mitochondrial changes in humans.  The issue for
peroxisome proliferators is the risk of hepatocarcinogenesis,
not peroxisome proliferation itself.  Hoivik et al.8 suggested
that the primate may be refractory to PPAR-induced
hepatocarcinogenesis because cynomolgus monkeys
responded to fibrates in a manner that is different from the
rodent; that is to say, there was no indication of cell
proliferation, and there was no remarkable increase in the
mRNA levels for most proteins known to respond to
oxidative stress.  In fact, there have been no reports showing
that peroxisome proliferators cause hepatocarcinogenesis in
nonhuman primates or humans.  Cynomolgus monkeys are
now widely used as models in risk assessment of new
chemicals and drugs.  The response to peroxisome
proliferators in cynomolgus monkeys was considered to be
closer to that in humans than the response in rodents.
However, further investigation into the causes of species
differences appears to be necessary for accurate assessments
of the risk of peroxisome proliferators for humans from the
results in cynomolgus monkeys.
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